FAQ about corrections to “Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity”

FAQ about corrections to “Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity” by Reynolds et al. Circulation September 2021

Two correction notices were recently issued about “Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity” in Circulation. Why were they needed? 

  • The first corrected typographical errors in the number of participants in various CAD categories within two tables in the supplement. The data were correct in the manuscript and in the rest of the supplement. The error occurred during copying and pasting of data from a statistical report into the supplement. The correction notice appears here.
  • The second clarified how the analytic cohort was derived (n=2475). We excluded from the analysis 43 randomized participants with CCTA showing left main disease (protected or unprotected) or showing no obstructive CAD. The correction notice appears here.

The Circulation readers who identified the errors leading to these corrections asked additional questions online. These additional questions did not require correction or clarification in the article. However, we provide additional clarifications here: https://ischemiatrial.org/.

We are grateful to the readers for calling our attention to the errors in the supplement and we regret having made these errors. We appreciate the opportunity offered by Circulation to provide corrections to the article.

Did the published corrections change the interpretation of the data?

No. They did not change the results or their interpretation. We only corrected typographical errors and clarified how the cohort was selected. 

Why is there so much controversy on social media, especially Twitter, about these corrections?

ISCHEMIA is a high profile trial, with major implications for clinical practice, and accordingly is subject to intense scrutiny. ISCHEMIA has published over 30 peer-reviewed articles to date, and you should be proud of your contribution. We stand by the integrity of the data we have published. We will continue to adhere to the highest scientific standards.

Will ISCHEMIA data be shared with the public?

Yes. The data sharing platform is NHLBI BioData Catalyst. It is open to all researchers. The process of making ISCHEMIA data available within BioData Catalyst is underway.